

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司\***  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 1548)

**(1) POSTPONEMENT OF ANNUAL GENERAL MEETING,  
(2) CHANGE OF DATES FOR CLOSURE OF REGISTER OF MEMBERS AND  
(3) DESPATCH OF SUPPLEMENTAL CIRCULAR, SUPPLEMENTAL NOTICE  
AND REVISED FORM OF PROXY**

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.73 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

**POSTPONEMENT OF ANNUAL GENERAL MEETING**

Reference is made to the circular of the Company (the “**AGM Circular**”) and the notice (the “**AGM Notice**”) of annual general meeting of the Company (the “**AGM**”) both dated 22 April 2024 in relation to, among other things, the AGM. Pursuant to the AGM Notice, the AGM was scheduled to be held at Conference Room, 208 Longmian Avenue, Jiangning District, Nanjing, Jiangsu Province, PRC on Friday, 17 May 2024 at 9:30 a.m.

In accordance with article 62 of the articles of association of the Company (as amended, supplemented or otherwise modified from time to time), each annual general meeting of the Company shall be held within six months after the end of the Company’s financial year (or any longer period authorised by the Stock Exchange) in the relevant territory or elsewhere, as may be determined by the Board, and at such time and place as the Board shall appoint.

As disclosed in the AGM Circular, Dr. Wang Luquan (“**Dr. Wang**”) shall retire at the Annual General Meeting. The AGM Circular further stated that Dr. Wang would not offer himself for re-election at the Annual General Meeting. Since the release of the AGM Circular and the Notice, it has come to the attention of the Board that, Dr. Wang desires to offer himself for re-election at the AGM.

Accordingly, additional resolution will be proposed at the AGM regarding the re-election of Dr. Wang as a non-executive Director. The Board has resolved and hereby announces that, due to the additional resolution to be submitted to the shareholders of the Company (the “**Shareholders**”) for their consideration and the additional time required by the Company to prepare for the relevant resolution, the Company hereby postpones the AGM (the “**Postponed AGM**”) to a date falling on or before 30 June 2024 (the “**Postponement of the AGM**”).

The supplemental circular, containing among other things, the details of the additional resolution to be considered at the Postponed AGM will be despatched to the Shareholders in due course.

## **CHANGE OF DATES FOR CLOSURE OF REGISTER OF MEMBERS**

As set out in the AGM Circular, the register of members of the Company is originally scheduled to be closed from Monday, 13 May 2024 to Friday, 17 May 2024, both days inclusive, during which period no transfer of shares of the Company will be registered, in order to determine the identity of the Shareholders who are entitled to attend and vote at the AGM.

Due to the Postponement of the AGM, the period during which the register of members will be closed in order to determine the identity of the Shareholders who are entitled to attend and vote at the Postponed AGM (during which period no share transfers will be registered) will also be changed. The revised period during which the register of members will be closed will be announced together with the revised date of the Postponed AGM.

## **DESPATCH OF SUPPLEMENTAL CIRCULAR, SUPPLEMENTAL NOTICE AND REVISED FORM OF PROXY**

The supplemental circular and supplemental notice of the Postponed AGM together with the revised form of proxy (the “**Revised Form of Proxy**”), containing among other things, the additional resolution to be considered, will be despatched to the Shareholders and published on the websites of the Stock Exchange and the Company in due course.

Special arrangements for the completion and return of the Revised Form of Proxy will also be set out in the supplemental notice of the Postponed AGM. Shareholders who have appointed or intend to appoint any proxy to attend the Postponed AGM are requested to pay particular attention to the special arrangements to be set out therein.

By order of the Board  
**GenScript Biotech Corporation**  
**MENG Jiange**  
Chairman and Executive Director

Hong Kong, 16 May 2024

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan, Dr. Wang Xuehai, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang.*

*\* For identification purposes only*